SAFETY

LINZESS was evaluated in a phase 3 placebo-controlled trial including 328 pediatric patients 6 to 17 years of age with functional constipation1,2

FC LINZESS adverse reactions
1 patient/<1% of LINZESS-treated patients reported severe diarrhea vs 0 placebo-treated patients1
1 patient/<1% of LINZESS-treated patients discontinued due to severe diarrhea vs 0 placebo-treated patients1

Most reported cases of diarrhea started within the first 2 weeks of LINZESS treatment.1